Google Übersetzer
About
Biovaxys Technology Corp (CN:BIOV) — investor relations, events, news, and company updates on 6ix.
Latest News
Jan 29 2026
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
Jan 20 2026
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Jan 8 2026
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Dec 17 2025
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Nov 19 2025
BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement
Recent Videos
Medical Innovations Roundup
Mar 10, 2026
Energy and Innovation Updates in OTC Market
Mar 10, 2026
BioVaxys Technology: Phase 1 Data Signals Breakthrough in Breast Cancer Therapy
Dec 23, 2025
BioVaxys is building something completely different #stocks #investing #stockmarket #finance
Dec 15, 2025
Financials
Revenue
CA$0
Market Cap
CA$2.64 M
EPS
-0.24